A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
COPD Exacerbation Acute
Interventions
DRUG

Sitafloxacin

Oral administration, 50 mg tablets

DRUG

Moxifloxacin Hydrochloride

Oral administration, 400 mg tablets

Trial Locations (18)

100144

Peking University Shougang Hospital, Beijing

116011

The First Affiliated Hospital of Dalian Medical University, Dalian

200433

Huadong Hospital Affiliated To Fudan University, Shanghai

221004

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

236000

Fuyang People's Hospital, Fuyang

250012

Qilu Hospital of Shandong University, Jinan

300070

Tianjin Medical University General Hospital, Tianjin

410013

The Third Xiangya Hospital of Central South University, Changsha

430000

The Sixth Hospital of Wuhan, Wuhan

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450003

Henan Provincial People's Hospital, Zhengzhou

510510

Nanfang Hospital Southern Medical University, Guangzhou

518140

Shenzhen People's Hospital, Shenzhen

523710

Affiliated Hospital of Guangdong Medical University, Zhanjiang

525200

Gaozhou People's Hospital, Maoming

610000

The Sixth People's Hospital of Chengdu, Chengdu

610041

West China Hospital Sichuan University, Chengdu

075001

The First Affiliated Hospital of Hebei North University, Zhangjiakou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY